Sage Therapeutics — Q2 2024 Earnings Presentation
13 slides from Sage Therapeutics's earnings presentation, Jul 31, 2024
Slide 1: Second Quarter 2024 Financial Results
Second Quarter 2024 Financial Results July 31, 2024
Slide 2: Safe Harbor Statement
Safe Harbor Statement – At any stage, regulatory authorities may ask for additional clinical trials, nonclinical studies or other data in order for us to proceed further in development or to file for or obtain regulatory approval. Other decisions • The slides presented today and the accompanying ora
Slide 3: Sage Therapeutics call participants
Sage Therapeutics call participants Barry Greene Chris Benecchi Laura Gault Kimi Iguchi Mike Quirk Chief Executive Officer Chief Business Officer Chief Medical Officer Chief Financial Officer Chief Scientific Officer Sage The rapeutics © 2024 3
Slide 4: Patient inspired, patient led, patient first
Patient inspired, patient led, patient first ZURZUVAE® First and only oral product Differentiated pipeline approved by the FDA specifically driven by patient need, science, for postpartum depression and external insights (second approved product) Scientific and therapeutic Strong financial foundatio
Slide 5: Strong ZURZUVAE performance in the second quarter
Strong ZURZUVAE performance in the second quarter Strong demand with ~2,000 prescriptions in Q2; >60% increase from Q1 to Q2 More than 1,400 shipments delivered to patients; >95% increase in shipments from Q1 to Q2 Total revenue of $14.8M; 19% increase from Q1 to Q2 Continued HCP prescriber momentum
Slide 6: Commercial Products and Pipeline
COMPOUND TARGET INDICATIONS PHASE 1 PHASE 2 PHASE 3 STATUS Postpartum Depression Commercial Products ZURZUVAE®* M A R KE T ED Postpartum Depression (zuranolone) CIV ZULRESSO ® M A R KE T ED Postpartum Depression (brexanolone) CIV injection Pipeline Zuranolone* Major Depressive Disorder** P H AS E 3
Slide 7: ZURZUVAE Q2 2024 PPD Launch Update
ZURZUVAE Q2 2024 PPD Launch Update PRESCRIPTION DATA* PHYSICIAN TRENDS* COVERAGE UPDATES* • ~2,000 prescriptions of • OBGYNs accounted for over • ~80% of all commercial lives ZURZUVAE written in Q2 70% of prescriptions, followed covered • More than 1,400 prescriptions by psychiatrists and PCPs • 2 o
Slide 8: Phase 2 data expected for dalzanemdor (SAGE-718) in HD and AD in late 2024
Phase 2 data expected for dalzanemdor (SAGE-718) in HD and AD in late 2024 M ID 2 0 2 4 ( Q2 /Q 3 ) LATE 2 0 2 4 ( Q3 /Q 4 ) • Topline data from the SURVEYOR Study in HD • Topline data from the LIGHTWAVE Study in AD • Topline data from the DIMENSION Study in HD HD = Huntington's Disease, AD = Alzhei
Slide 9: KINETIC 2 Data Summary
KINETIC 2 Data Summary The Phase 2 KINETIC 2 Study was a double-blind, randomized, placebo-controlled, dose- response study to evaluate efficacy, safety, and tolerability of SAGE-324 (BIIB124) 15 mg, 30 mg, and 60 mg (with uptitration) in participants with ET (N = 147 [monotherapy cohort, n = 129]).
Slide 10: Other potential areas of growth within GABA and NMDA platforms
Other potential areas of growth within GABA and NMDA platforms Profile Preclinical profile of SAGE-319 of SAGE-421 GABA Receptor PAM NMDA Receptor PAM • Extra-synaptic GABAA receptor • NMDA receptor positive preferring positive allosteric allosteric modulator modulator • Profile intended to support
Slide 11: Second Quarter 2024 Financial Results
Second Quarter 2024 Financial Results Strong financial foundation with $0.6B in cash at the end of Q2 ’24 Item Q2 ’24 Q2 ’23 Product revenue, net $0.6M $2.5M License and milestone revenue - related party $0M $0M Collaboration revenue - related party $7.4M $0M Other Collaboration revenue $0.6M $0M To
Slide 12: Potential Value Creating Catalysts
Potential Value Creating Catalysts Anticipated Events Ongoing commercialization of ZURZUVAE in the treatment of women with PPD 2 02 4 ZURZUVAE* Present analyses of real-world evidence for ZURZUVAE including health economics 2 02 4 and patient reported outcomes Topline data from the PRECEDENT Study i
Slide 13: Q&A
Q&A Sage The rapeutics © 2024 13